March 2015, Vol 8, Sixth Annual Payers' Guide
Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death
In the United States, heart disease is the number one cause of death, claiming the lives of approximately 600,000 people annually—a staggering 1 in every 4 deaths. Coronary heart disease (CHD) alone accounts for nearly 380,000 deaths yearly. Myocardial infarction (MI) is a common type of CHD affecting 720,000 Americans every year. Of these total MIs, 515,000 are first MIs, and 205,000 are recurrent MIs.
Zydelig (Idelalisib): First-in-Class PI3 Kinase Inhibitor Approved for the Treatment of 3 Hematologic Malignancies
Chronic lymphocytic leukemia (CLL), a cancer of B-cell lymphocytes, is the most common type of leukemia in Western adult patients. According to the Leukemia and Lymphoma Society, more than 15,600 Americans were diagnosed with CLL in 2013.
Zykadia (Ceritinib) Approved for Patients with Crizotinib-Resistant ALK-Positive Non–Small-Cell Lung Cancer
Lung cancer is one of the most frequently diagnosed cancers, as well as the leading cause of cancer-related mortality in the United States. According to the American Cancer Society, more than 159,000 Americans will die from lung cancer in 2014, representing approximately 27% of all cancer deaths. Non–small-cell lung cancer (NSCLC), the most common form of lung cancer, accounts for 85% to 90% of all cases. NSCLC comprises a number of histologies, including adenocarcinoma, squamous-cell carcinoma, nonsquamous carcinoma, large-cell carcinoma, sarcomatoid carcinoma, and adenosquamous carcinoma.
For patients, newly approved drugs represent exciting opportunities to treat serious disease states, many of which have had few treatment options available. New therapies have enabled physicians to initiate treatment earlier and to continue treatment throughout the disease progression. The goal of early therapy is to alleviate the long-term effects of chronic or life-threatening conditions, but when treatment occurs earlier and lasts longer, the cost of therapy also increases.
Glyxambi (Empagliflozin/Linagliptin): A Dual- Acting Oral Medication Approved for the Treatment of Patients with Type 2 Diabetes
Lenvima (Lenvatinib), a Multireceptor Tyrosine Kinase Inhibitor, Approved by the FDA for the Treatment of Patients with Differentiated Thyroid Cancer
Thyroid cancer, cancer that starts in the thyroid gland, accounts for 3.8% of all cancer cases in the United States. There were an estimated 62,980 new cases of thyroid cancer and 1890 deaths resulting from thyroid cancer in 2014. Thyroid cancer is most common in people aged 45 to 54 years (median age, 50 years), and it occurs 2 to 3 times more often in women than in men. The incidence of thyroid cancer has risen steadily in recent years. Although this increasing rate can be attributed largely to disease detection at an earlier stage, the incidence of larger tumors has also increased.
Opdivo (Nivolumab): Second PD-1 Inhibitor Receives FDA Approval for Unresectable or Metastatic Melanoma
Although less common than other skin cancers, melanoma is the most dangerous form of skin cancer. According to data collected between 2004 and 2010, the 5-year relative survival rate for Americans with distant melanoma is only 16% for all ages, races, and sexes. The National Cancer Institute estimated that there were 76,100 new cases of skin melanoma in 2014, and more than 9700 patients died from this disease during the same period. The incidence of melanoma continues to rise, particularly among children and adolescents.
Page 3 of 3
Results 21 - 27 of 27
Results 21 - 27 of 27